Evidence of HIV incidence reduction in young women, but not in adolescent girls, in KwaZulu-Natal, South Africa.
ART
Cross-sectional surveys
HIV
Incidence
Prevalence
Recency tests
Journal
IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
05
05
2023
revised:
07
07
2023
accepted:
10
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
We estimated changes in the HIV incidence from 2013-2018 in Eshowe/Mbongolwane, KwaZulu-Natal, South Africa where Médecins Sans Frontières is engaged in providing HIV testing and care since 2011. Using data from two cross-sectional household-based surveys conducted in 2013 and 2018, with consenting participants aged 15-59 years, we applied the incidence estimation frameworks of Mahiane et al and Kassanjee et al. In total, 5599 (62.4% women) and 3276 (65.9% women) individuals were included in 2013 and 2018, respectively. We found a mean incidence in women aged 20-29 years of 2.71 cases per 100 person-years (95% confidence interval [CI]: 1.23;4.19) in 2013 and 0.4 cases per 100 person-years (95% CI: 0.0;1.5) in 2018. The incidence in men aged 20-29 years was 1.91 cases per 100 person-years (95% CI: 0.87; 2.93) in 2013 and 0.53 cases per 100 person-years (95% CI: 0.0; 1.4) in 2018. The incidence decline among women aged 15-19 was -0.34 cases per 100 person-years (95% CI: -1.31;0.64). The lack of evidence of incidence decline among adolescent girls is noteworthy and disconcerting. Our findings suggest that large-scale surveys should seriously consider focusing their resources on the core group of women aged 15-19 years.
Identifiants
pubmed: 37577330
doi: 10.1016/j.ijregi.2023.07.004
pii: S2772-7076(23)00074-7
pmc: PMC10415685
doi:
Types de publication
Journal Article
Langues
eng
Pagination
111-117Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
PLoS One. 2022 Mar 24;17(3):e0265488
pubmed: 35324923
Lancet HIV. 2022 Nov;9(11):e781-e790
pubmed: 36075252
J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):443-51
pubmed: 24815854
Lancet HIV. 2021 Jul;8(7):e389-e390
pubmed: 34197769
PLoS Med. 2021 Oct 25;18(10):e1003837
pubmed: 34695112
BMC Public Health. 2018 Mar 2;18(1):303
pubmed: 29499668
Lancet HIV. 2017 Jan;4(1):e41-e50
pubmed: 27914874
PLoS One. 2018 Oct 16;13(10):e0203193
pubmed: 30325932
AIDS. 2016 Sep 24;30(15):2361-71
pubmed: 27454561
Lancet Glob Health. 2019 Nov;7(11):e1521-e1540
pubmed: 31607465
J Int AIDS Soc. 2020 Sep;23 Suppl 5:e25575
pubmed: 32869481
PLoS One. 2012;7(9):e44377
pubmed: 22984497
Lancet HIV. 2018 Nov;5(11):e667-e670
pubmed: 30314745
Int J Environ Res Public Health. 2022 Jul 01;19(13):
pubmed: 35805784
AIDS. 2014 Oct 23;28(16):2439-49
pubmed: 25144218
South Afr J HIV Med. 2017 Jul 27;18(1):694
pubmed: 29568630
Epidemiology. 2012 Sep;23(5):721-8
pubmed: 22627902
PLoS One. 2018 Sep 13;13(9):e0203638
pubmed: 30212513
South Afr J HIV Med. 2021 Mar 10;22(1):1205
pubmed: 33824738
BMC Public Health. 2022 May 14;22(1):973
pubmed: 35568839
AIDS. 2017 Jun 19;31(10):1461-1470
pubmed: 28426534
J Int AIDS Soc. 2021 Oct;24(10):e25818
pubmed: 34672104